Bimekizumab en Pacientes con Artritis Psoriásica Activa y Respuesta Previa Inadecuada o Intolerancia a Inhibidores de Factor de Necrosis Tumoral-α: Un Ensayo clínico de fase 3, aleatorizado, doble ciego y controlado con placebo (BE COMPLETE)

Lancet. 2023 doi: 10.1016/S0140-6736(22)02303-0

This study showed rapid and clinically meaningful improvements with bimekizumab treatment in patients experiencing active PsA and showing an inadequate response or intolerance to TNFα inhibitors. Its chief aim was to evaluate the efficacy and safety of bimekizumab in patients with an inadequate response or intolerance to TNFα inhibitors.

Keywords:


Publication thumbnail: Bimekizumab en Pacientes con Artritis Psoriásica Activa y Respuesta Previa Inadecuada o Intolerancia a Inhibidores de Factor de Necrosis Tumoral-α: Un Ensayo clínico de fase 3, aleatorizado, doble ciego y controlado con placebo (BE COMPLETE)
LinkedIn